A "drug cocktail" delivered by microspheres for the local treatment of rat glioblastoma

Journal of Microencapsulation

Volumn 30, Issue 7, 2013, Pages 667-673

  Allhenn, Daniela ^a   Neumann, Dirk ^a   Béduneau, Arnaud ^b   Pellequer, Yann ^b   Lamprecht, Alf ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Brain delivery; Local glioblastoma therapy; Microsized implants; Microspheres

Indexed keywords

CELECOXIB; ELACRIDAR; ETOPOSIDE; MICROSPHERE; POLYGLACTIN; WATER OIL CREAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RELEASE; DRUG SOLUBILITY; EVAPORATION; GLIOBLASTOMA; LIPOPHILICITY; MALE; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; TUMOR VOLUME;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYCLOOXYGENASE 2 INHIBITORS; DRUG CARRIERS; ETOPOSIDE; GLIOBLASTOMA; LACTIC ACID; MALE; MICROSPHERES; POLYGLYCOLIC ACID; PYRAZOLES; RATS; RATS, INBRED F344; SULFONAMIDES; TETRAHYDROISOQUINOLINES;

EID: 84885334226     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2013.774446     Document Type: Article

References (36)

1. Allhenn D, Lamprecht A. Microsphere preparation using the untoxic solvent glycofurol. Pharm Res, 2011;28:563-71.
2. Arosarena O, Guerin C, Brem H, Laterra J. Endothelial differentiation in intracerebral and subcutaneous experimental gliomas. Brain Res, 1994;640:98-104.
3. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol, 2005;511:191-8.
4. Ayubk O. Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet, 1963;282:983-4.
5. Bakhshi S, North RB. Implantable pumps for drug delivery to the brain. J Neurooncol, 1995;26:133-9.
6. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA, 1994;91:2076-80.
7. Brem H, Mahaley Jr MS, Vick NA, Black KL, Schold Jr SC, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg, 1991;74:441-6.
8. Dantzig AH, De Alwis DP, Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev, 2003;55:133-50.
9. Di Paolo A, Bocci G. Drug distribution in tumors: Mechanisms, role in drug resistance, and methods for modification. Curr Oncol Rep, 2007;9:109-14.
10. Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol, 2000;53:458-64.
11. Garfield J, Dayan AD. Postoperative intracavitary chemotherapy of malignant gliomas. A preliminary study using methotrexate. J Neurosurg, 1973;39:315-22.
12. Groothuis DR. The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro Oncol, 2000;2:45-59.
13. Guo A, Marinaro W, Hu P, Sinko PJ. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos, 2002;30:457-63.
14. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev, 2011;3:CD007294.
15. Hassenbusch SJ, Nardone EM, Levin VA, Leeds N, Pietronigro D. Stereotactic injection of DTI-015 into recurrent malignant gliomas: Phase I/II trial. Neoplasia, 2003;5:9-16.
16. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, Seyfried NT, Abe T, Chen LB, Carroll RS, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res, 2000;60:4926-31.
17. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro Oncol, 1999;1:44-51.
18. Lamprecht A, Benoit JP. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release, 2006;112:208-13.
19. Li KW, Dang W, Tyler BM, Troiano G, Tihan T, Brem H, Walter KA. Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies. Clin Cancer Res, 2003;9:3441-7.
20. Menei P, Capelle L, Guyotat J, Fuentes S, Assaker R, Bataille B, Francois P, Dorwling-Carter D, Paquis P, Bauchet L, et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosen-sitization of malignant glioma: A randomized phase II trial. Neurosurgery, 2005;56:242-8; discussion 242-8.
21. Menei P, Jadaud E, Faisant N, Boisdron-Celle M, Michalak S, Fournier D, Delhaye M, Benoit JP. Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer, 2004;100:405-10.
22. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer, 2006;6:583-92.
23. Padowski JM, Pollack GM. Examination of the ability of the nasal administration route to confer a brain exposure advantage for three chemical inhibitors of P-glycoprotein. J Pharm Sci, 2010;99:3226-33.
24. Pelis RM, Shahidullah M, Ghosh S, Coca-Prados M, Wright SH, Delamere NA. Localization of multidrug resistance-associated protein 2 in the nonpigmented ciliary epithelium of the eye. J Pharmacol Exp Ther, 2009;329:479-85.
25. Rhines LD, Sampath P, Dimeco F, Lawson HC, Tyler BM, Hanes J, Olivi A, Brem H. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: A novel treatment for experimental malignant glioma. Neurosurgery, 2003;52:872-9; discussion 879-80.
26. Roullin VG, Lemaire L, Venier-Julienne MC, Faisant N, Franconi F, Benoit JP. Release kinetics of 5-fluorouracil-loaded microspheres on an experimental rat glioma. Anticancer Res, 2003;23:21-5.
27. Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M, Delattre JY. Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: A phase II study. Eur J Cancer, 1996;32A:2229-35.
28. Schinkel AH, Wagenaar E, Mol CA, Van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest, 1996;97:2517-24.
29. Shirazi FH, Bahrami G, Stewart DJ, Tomiak E, Delorme F, Noel D, Goel R. A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. J Pharm Biomed Anal, 2001;25:353-6.
30. Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, Reppas C, Dressman JB. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm, 2009;73:107-14.
31. Siepmann J, Siepmann F. Mathematical modeling of drug delivery. Int J Pharm, 2008;364:328-43.
32. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmacol Sci, 2003;24:96-102.
33. Totzke G, Schulze-Osthoff K, Janicke RU. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene, 2003;22: 8021-30.
34. Tunggal JK, Melo T, Ballinger JR, Tannock IF. The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multi-cellular layers. Int J Cancer, 2000;86:101-7.
35. Vinchon-Petit S, Jarnet D, Michalak S, Lewis A, Benoit JP, Menei P. Local implantation of doxorubicin drug eluting beads in rat glioma. Int J Pharm, 2010;402:184-9.
36. Watanabe K, Kanaya H, Fujiyama Y, Kim P. Combination chemotherapy using carboplatin (jm-8) and etoposide (jet therapy) for recurrent malignant gliomas: A phase ii study. Acta Neurochir, 2002;144:1265-70.